MarketPeel
Insider Trading Intelligence
DH

Dawn Halkuff

XERS
DIRECTOR · XERIS BIOPHARMA HOLDINGS, INC. · CIK 0001743658
FILING MIX · LIFETIME72%/28%
BUYS
13
SELLS
5
TOTAL VALUE
$644.0K
COMPANIES
1
ACTIVE SINCE
Jun 2020
HOLDINGS NOW
95,000
AVG SELL PX
$6.90
TRADE KIND
SHOWING 18 / 18
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons · 2 pending
Forward-return performance of every backtestable P/S trade by Dawn Halkuff, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+50.00%+0.96%-0.20%+1.16%+1.16%
14d2+50.00%+6.38%+0.46%+5.92%+5.92%
30d2+50.00%+7.82%+2.91%+4.91%+4.91%
60d2+50.00%+20.93%+4.12%+16.82%+16.82%
90d2+50.00%+41.34%+8.22%+33.12%+33.12%
180d2+100.00%+2.07%+12.68%-10.62%-10.62%
1y2(1 pending)+100.00%+65.39%+31.70%+33.68%+33.68%
2y2(1 pending)+100.00%+289.56%+48.79%+240.78%+240.78%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
XERS · 95,000 shares · as of Jun 4, 2026
039,37578,750118,125157,500202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 13 buys / 5 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
XERS
XERIS BIOPHARMA HOLDINGS, INC.
SALE10b5-1
10b5-1 plan
20,000$6.09$121.9K95,000Jun 4, 2026Jun 5, 2026View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
32,996$6.15$202.9K32,996Jun 4, 2026Jun 5, 2026View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
24,193119,193Jun 4, 2026Jun 5, 2026View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
SALE
42,500$7.28$309.2K115,000Aug 12, 2025Aug 13, 2025View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
50,000157,500Jun 4, 2025Jun 4, 2025View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
50,000107,500Jun 5, 2024Jun 5, 2024View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASE
5,410$1.84$10.0K5,410Nov 20, 2023Nov 21, 2023View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
42,50057,500Jun 7, 2023Jun 7, 2023View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
15,00015,000Jun 8, 2022Jun 9, 2022View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
25,00025,000Jun 8, 2022Jun 9, 2022View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
SALE
20,0000Oct 5, 2021Oct 5, 2021View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
SALE
19,6500Oct 5, 2021Oct 5, 2021View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
SALE
11,2280Oct 5, 2021Oct 5, 2021View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
19,65019,650Oct 5, 2021Oct 5, 2021View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
11,22811,228Oct 5, 2021Oct 5, 2021View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
20,00020,000Oct 5, 2021Oct 5, 2021View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
11,22811,228Jun 8, 2021Jun 8, 2021View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
11,22811,228Jun 4, 2020Jun 4, 2020View →
Other insiders · XERS
Loading peer insiders…
About this filer
CIK 0001743658
ROLE
Director
PRIMARY
XERS
COMPANIES
1
ACTIVE SINCE
Jun 2020
MARKETPEEL · /INSIDER/0001743658DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback